Publications

  1. Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak MA, Hornberger J. Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer. Pharmacoeconomics. 2014 Dec; 32(12):1231-43.
    View PubMed
  2. Renfro LA, Grothey A, Xue Y, Saltz LB, Andre T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. J Natl Cancer Inst. 2014 Dec; 106(12). Epub 2014 Oct 29.
    View PubMed
  3. Renfro LA, Shi Q, Xue Y, Li J, Shang H, Sargent DJ. Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints. Comput Stat Data Anal. 2014 Oct 1; 78:1-20.
    View PubMed
  4. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C, Aide et Recherche en Cancerologie Digestive Foundation. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20; 32(27):2975-84.
    View PubMed
  5. Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in Oncology. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014 Sep; 147(3):637-45. Epub 2014 May 21.
    View PubMed
  6. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Jul 07.
    View PubMed
  7. Renfro LA, Shang H, Sargent DJ. Impact of copula directional specification on multi-trial evaluation of surrogate endpoints. J Biopharm Stat. 2014 Jun 06.
    View PubMed
  8. Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, Mazurczak M, Lee M, Alberts SR. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014 May; 19(5):492-7. Epub 2014 Apr 07.
    View PubMed
  9. Renfro LA, Coughlin CM, Grothey AM, Sargent DJ. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chin Clin Oncol. 2014 Mar 1; 3(1).
    View PubMed
  10. Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer. PLoS One. 2014; 9(4):e94727. Epub 2014 Apr 11.
    View PubMed
  11. Ryan C, Kelleher J, Fagan MF, Rogers S, Collins P, Barker JNWN, Allen M, Hagan R, Renfro L, Kirby B. Genetic markers of treatment response to tumour necrosis factor-alpha inhibitors in the treatment of psoriasis. Clin Exp Dermatol. 2014; 39(4):519-24.
  12. Renfro LA, Grothey AM, Paul J, Floriani I, Bonnetain F, Niedzwiecki D, Yamanaka T, Souglakis I, Yothers G, Sargent DJ for the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting event-based analysis dates in clinical trials: an illustration based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Forum of Clinical Oncology (in press). 2014.
  13. Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ Jr, Maizels N. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. PLoS One. 2014; 9(10):e108483. Epub 2014 Oct 13.
    View PubMed
  14. Renfro LA, Shi Q, Sargent DJ. Mining the ACCENT database: A review and update. Chinese Clinical Oncology. 2013 Jun; 2(2):18.
  15. Shafi S, Renfro LA, Barnes S, Rayan N, Gentilello LM, Fleming N, Ballard D. Chronic consequences of acute injuries: worse survival after discharge. J Trauma Acute Care Surg. 2012 Sep; 73(3):699-703.
    View PubMed
  16. Renfro LA, Shi Q, Sargent DJ, Carlin BP. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. Stat Med. 2012 Apr 13; 31(8):743-61. Epub 2011 Dec 09.
    View PubMed
  17. Renfro LA, Carlin BP, Sargent DJ. Bayesian adaptive trial design for a newly validated surrogate endpoint. Biometrics. 2012 Mar; 68(1):258-67. Epub 2011 Aug 12.
    View PubMed
  18. Renfro LA, Sargent DJ. Multi-trial databases for improved learning in oncology. Treatment Strategies in Oncology (Ebook) http://viewerzmagscom/publication/e049b37c#/e049b37c/1. 2012; 3(1):59-62.
  19. Shi Q, Renfro LA, Bot BM, Burzykowski T, Buyse M, Sargent DJ. Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. Computational Statistics and Data Analysis. 2011; 55(9):2748-57.
  20. Ryan C, Renfro L, Collins P, Kirby B, Rogers S. Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis. Br J Dermatol. 2010 Nov; 163(5):1056-63.
    View PubMed
  21. Renfro LA, Hamner MS. Predicting undergraduate re-enrollment: a Bayesian approach. The Pentagon (Kappa Mu Epsilon National Mathematics Honor Society). 2006; 62(2):7-20.